Western blot analysis of extracts of HEL, SH-SY5Y and NCCIT cells using Claspin Antibody.
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
From sample preparation to detection, the reagents you need for your Western Blot are now in one convenient kit: #12957 Western Blotting Application Solutions Kit
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 10
Claspin Antibody detects endogenous levels of total claspin protein.
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to amino acids near the carboxy terminus of human claspin. Antibodies are purified by peptide affinity chromatography.
Originally identified in Xenopus (1), and later in human cells (2), claspin is a mediator of Chk1 signal transduction at the replication checkpoint and in response to DNA damage. Expression of claspin is cell cycle-regulated, with protein levels peaking at the S/G2 phase (2). Expression is negatively regulated by both proteosome- and caspase-mediated degradation (3), and stabilized by activation of Chk1 (4). Claspin is a chromatin-bound protein, and has been shown to interact with the PNCA complex in the absence of DNA damage (5). Following checkpoint activation it remains chromatin-bound but is released from the PCNA complex and is phosphorylated in an ATR-dependent manner. Phosphorylated claspin interacts with several components of the DNA damage response including BRCA1 (6) and Chk1 (7), leading to ATR-dependent phosphorylation on each of these proteins. Phosphorylated Rad17 has also been shown to bind to and regulate the phosphorylation of claspin (8). It has been proposed that claspin behaves as a tumor suppressor in come cases since down-regulation promotes apoptosis following genotoxic stress (2). Conversely, claspin seems to behave as an oncogene in other instances since overexpression promotes cellular proliferation (6). Upregulated claspin has been suggested to be a sensitive marker of abnormally proliferating cells (9).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.